Selected genetically engineered models relevant to human neurodegenerative disease

Donald L. Price, David R. Borchelt, Michael K. Lee, Philip Chun Wong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction, This review on selected neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease, and frontotemporal dementia with Parkinsonism (FTD-P), focuses on the ways by which genetically engineered models have clarified the mechanisms of these disorders and have identified new targets for therapy, and been used to test new treatment strategies. These neurodegenerative diseases are some of the most challenging diseases in medicine because of their general prevalence, cost, lack of mechanism-based treatments, and impact on individuals and caregivers (Lipp & Wolfer, 1998; Wong et al., 2002). The classical clinical phenotypes are, for the most part, quite distinct and reflect the dysfunction and death of specific populations of neurons. These brain lesions are characterized by the presence of intracellular or extracellular peptides/aggregates, which appear to be critical contributors to neurotoxicity, partially damaging to synapses. Genetic risk factors influence these age-associated, chronic illnesses. In rare instances, cases are inherited in Mendelian fashion (usually as autosomal dominants). Susceptibility genes, environmental risk factors, or other influences remain to be defined. Information from genetics has allowed investigators to express or to target genes in efforts to model these diseases and to study the (Armstrong et al., 1996) molecular participants critical in pathogenic pathways. This body of research is the principal topic of this review. In this review, we emphasize the value of genetically engineered mouse models for studies of mechanisms and for experimental therapeutics, but we also briefly describe the extraordinary utility of non-mammalian genetic models.

Original languageEnglish (US)
Title of host publicationNeurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics
PublisherCambridge University Press
Pages176-195
Number of pages20
ISBN (Print)9780511544873, 052181166X, 9780521811668
DOIs
StatePublished - Jan 1 2005

Fingerprint

Neurodegenerative Diseases
Frontotemporal Dementia
Genetic Models
Amyotrophic Lateral Sclerosis
Therapeutics
Synapses
Caregivers
Genes
Parkinson Disease
Alzheimer Disease
Chronic Disease
Research Personnel
Medicine
Phenotype
Neurons
Costs and Cost Analysis
Peptides
Brain
Research
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Price, D. L., Borchelt, D. R., Lee, M. K., & Wong, P. C. (2005). Selected genetically engineered models relevant to human neurodegenerative disease. In Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics (pp. 176-195). Cambridge University Press. https://doi.org/10.1017/CBO9780511544873.016

Selected genetically engineered models relevant to human neurodegenerative disease. / Price, Donald L.; Borchelt, David R.; Lee, Michael K.; Wong, Philip Chun.

Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. Cambridge University Press, 2005. p. 176-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Price, DL, Borchelt, DR, Lee, MK & Wong, PC 2005, Selected genetically engineered models relevant to human neurodegenerative disease. in Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. Cambridge University Press, pp. 176-195. https://doi.org/10.1017/CBO9780511544873.016
Price DL, Borchelt DR, Lee MK, Wong PC. Selected genetically engineered models relevant to human neurodegenerative disease. In Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. Cambridge University Press. 2005. p. 176-195 https://doi.org/10.1017/CBO9780511544873.016
Price, Donald L. ; Borchelt, David R. ; Lee, Michael K. ; Wong, Philip Chun. / Selected genetically engineered models relevant to human neurodegenerative disease. Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. Cambridge University Press, 2005. pp. 176-195
@inbook{55ed294ad21547738755f256716331f2,
title = "Selected genetically engineered models relevant to human neurodegenerative disease",
abstract = "Introduction, This review on selected neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease, and frontotemporal dementia with Parkinsonism (FTD-P), focuses on the ways by which genetically engineered models have clarified the mechanisms of these disorders and have identified new targets for therapy, and been used to test new treatment strategies. These neurodegenerative diseases are some of the most challenging diseases in medicine because of their general prevalence, cost, lack of mechanism-based treatments, and impact on individuals and caregivers (Lipp & Wolfer, 1998; Wong et al., 2002). The classical clinical phenotypes are, for the most part, quite distinct and reflect the dysfunction and death of specific populations of neurons. These brain lesions are characterized by the presence of intracellular or extracellular peptides/aggregates, which appear to be critical contributors to neurotoxicity, partially damaging to synapses. Genetic risk factors influence these age-associated, chronic illnesses. In rare instances, cases are inherited in Mendelian fashion (usually as autosomal dominants). Susceptibility genes, environmental risk factors, or other influences remain to be defined. Information from genetics has allowed investigators to express or to target genes in efforts to model these diseases and to study the (Armstrong et al., 1996) molecular participants critical in pathogenic pathways. This body of research is the principal topic of this review. In this review, we emphasize the value of genetically engineered mouse models for studies of mechanisms and for experimental therapeutics, but we also briefly describe the extraordinary utility of non-mammalian genetic models.",
author = "Price, {Donald L.} and Borchelt, {David R.} and Lee, {Michael K.} and Wong, {Philip Chun}",
year = "2005",
month = "1",
day = "1",
doi = "10.1017/CBO9780511544873.016",
language = "English (US)",
isbn = "9780511544873",
pages = "176--195",
booktitle = "Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Selected genetically engineered models relevant to human neurodegenerative disease

AU - Price, Donald L.

AU - Borchelt, David R.

AU - Lee, Michael K.

AU - Wong, Philip Chun

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Introduction, This review on selected neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease, and frontotemporal dementia with Parkinsonism (FTD-P), focuses on the ways by which genetically engineered models have clarified the mechanisms of these disorders and have identified new targets for therapy, and been used to test new treatment strategies. These neurodegenerative diseases are some of the most challenging diseases in medicine because of their general prevalence, cost, lack of mechanism-based treatments, and impact on individuals and caregivers (Lipp & Wolfer, 1998; Wong et al., 2002). The classical clinical phenotypes are, for the most part, quite distinct and reflect the dysfunction and death of specific populations of neurons. These brain lesions are characterized by the presence of intracellular or extracellular peptides/aggregates, which appear to be critical contributors to neurotoxicity, partially damaging to synapses. Genetic risk factors influence these age-associated, chronic illnesses. In rare instances, cases are inherited in Mendelian fashion (usually as autosomal dominants). Susceptibility genes, environmental risk factors, or other influences remain to be defined. Information from genetics has allowed investigators to express or to target genes in efforts to model these diseases and to study the (Armstrong et al., 1996) molecular participants critical in pathogenic pathways. This body of research is the principal topic of this review. In this review, we emphasize the value of genetically engineered mouse models for studies of mechanisms and for experimental therapeutics, but we also briefly describe the extraordinary utility of non-mammalian genetic models.

AB - Introduction, This review on selected neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease, and frontotemporal dementia with Parkinsonism (FTD-P), focuses on the ways by which genetically engineered models have clarified the mechanisms of these disorders and have identified new targets for therapy, and been used to test new treatment strategies. These neurodegenerative diseases are some of the most challenging diseases in medicine because of their general prevalence, cost, lack of mechanism-based treatments, and impact on individuals and caregivers (Lipp & Wolfer, 1998; Wong et al., 2002). The classical clinical phenotypes are, for the most part, quite distinct and reflect the dysfunction and death of specific populations of neurons. These brain lesions are characterized by the presence of intracellular or extracellular peptides/aggregates, which appear to be critical contributors to neurotoxicity, partially damaging to synapses. Genetic risk factors influence these age-associated, chronic illnesses. In rare instances, cases are inherited in Mendelian fashion (usually as autosomal dominants). Susceptibility genes, environmental risk factors, or other influences remain to be defined. Information from genetics has allowed investigators to express or to target genes in efforts to model these diseases and to study the (Armstrong et al., 1996) molecular participants critical in pathogenic pathways. This body of research is the principal topic of this review. In this review, we emphasize the value of genetically engineered mouse models for studies of mechanisms and for experimental therapeutics, but we also briefly describe the extraordinary utility of non-mammalian genetic models.

UR - http://www.scopus.com/inward/record.url?scp=84927095299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927095299&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511544873.016

DO - 10.1017/CBO9780511544873.016

M3 - Chapter

AN - SCOPUS:84927095299

SN - 9780511544873

SN - 052181166X

SN - 9780521811668

SP - 176

EP - 195

BT - Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics

PB - Cambridge University Press

ER -